DexCom, Inc. $DXCM Shares Acquired by Quadrant Capital Group LLC

by · The Cerbat Gem

Quadrant Capital Group LLC boosted its position in DexCom, Inc. (NASDAQ:DXCM – Free Report) by 34.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,583 shares of the medical device company’s stock after purchasing an additional 2,437 shares during the period. Quadrant Capital Group LLC’s holdings in DexCom were worth $837,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently added to or reduced their stakes in DXCM. Andra AP fonden purchased a new stake in shares of DexCom in the second quarter valued at approximately $26,000. Zions Bancorporation National Association UT acquired a new position in DexCom in the 1st quarter valued at $27,000. Anderson Financial Strategies LLC purchased a new position in shares of DexCom during the 1st quarter worth $37,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of DexCom during the second quarter worth $45,000. Finally, Atlantic Union Bankshares Corp purchased a new stake in shares of DexCom in the second quarter valued at $70,000. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Wall Street Analyst Weigh In

DXCM has been the topic of several recent analyst reports. Robert W. Baird set a $82.00 target price on DexCom in a research report on Friday, October 31st. Morgan Stanley cut their price objective on shares of DexCom from $89.00 to $63.00 and set an “equal weight” rating on the stock in a report on Monday, November 10th. Citigroup decreased their target price on shares of DexCom from $85.00 to $75.00 and set a “buy” rating on the stock in a research report on Friday, October 31st. Oppenheimer lowered shares of DexCom from an “outperform” rating to a “market perform” rating in a research report on Monday, September 8th. Finally, Cowen reiterated a “buy” rating on shares of DexCom in a report on Friday, October 24th. Three investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, six have given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $86.73.

View Our Latest Analysis on DexCom

DexCom Price Performance

DXCM opened at $63.52 on Tuesday. DexCom, Inc. has a twelve month low of $54.11 and a twelve month high of $93.25. The firm has a market cap of $24.77 billion, a price-to-earnings ratio of 44.11, a PEG ratio of 1.43 and a beta of 1.40. The company has a current ratio of 1.52, a quick ratio of 1.35 and a debt-to-equity ratio of 0.48. The company has a fifty day simple moving average of $64.19 and a 200 day simple moving average of $75.60.

DexCom (NASDAQ:DXCM – Get Free Report) last posted its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.04. The company had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The firm’s revenue for the quarter was up 21.6% on a year-over-year basis. During the same period in the prior year, the company posted $0.45 EPS. DexCom has set its FY 2025 guidance at EPS. Equities research analysts expect that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Insider Transactions at DexCom

In other news, Director Bridgette P. Heller sold 1,012 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $58.07, for a total transaction of $58,766.84. Following the completion of the transaction, the director directly owned 27,031 shares in the company, valued at approximately $1,569,690.17. This represents a 3.61% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Kyle Malady sold 667 shares of the firm’s stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $80.86, for a total transaction of $53,933.62. Following the sale, the director directly owned 22,667 shares of the company’s stock, valued at $1,832,853.62. The trade was a 2.86% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 9,999 shares of company stock valued at $619,391 in the last three months. 0.32% of the stock is currently owned by company insiders.

DexCom Profile

(Free Report)

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.

Further Reading

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).